Navigation Links
Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Date:9/4/2009

BASKING RIDGE, N.J., Sept. 4 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Thomas Weisel Partners Healthcare Conference 2009 in Boston, MA at 9:45 AM on Friday, September 11, 2009 (EDT). Ms. McDonald's presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling dire
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... , Sept. 15, 2014 EnGeneIC, ... revolutionizing the treatment of cancer through the targeted ... announced that, together with the Asbestos Disease Research ... Institute New South Wales (NSW) Premier,s Award for ... recipients are the hospitals that will be involved ...
(Date:9/15/2014)... team of researchers led by Northeastern University has ... inter-nanotube junctions and a variety of nanocarbon structures ... and easily scalable, which will allow the researchers ... for use in applications ranging from electronic devices ... cars to sports equipment. , Their findings were ...
(Date:9/15/2014)... -- The chemistry, taste, and health effects of tea can ... by the nonprofit American Botanical Council (ABC). Recent research by ... effects on the phytochemical compounds in tea ( Camellia sinensis ... Ahmed in the Yunnan province of ... the future of medicinal botanicals. Dr. Ahmed,s report ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... 28 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will ... on Wednesday, September 3, 2008 at 9:10 a.m. ET, ... September 4,2008 at 11:30 a.m. ET, and at the ... Tuesday, September 9, 2008 at 10:55,a.m. ET. Mark G. ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... will present at the Thomas Weisel Partners,2008 Healthcare ... 4, 2008.,The conference is being held at the ... also announced that William Roberts, vice president,corporate communications ...
... 28 ThromboGenics NV,(Euronext Brussels: THR), a biotechnology ... disease and cancer, is today issuing a,business update ... period ending,June 30, 2008., During the first ... of,key milestones which have positioned the Company to ...
Cached Biology Technology:Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences 2ViroPharma to Present at Three September Healthcare Conferences 2ThromboGenics Announces Half Year Results 2008 2ThromboGenics Announces Half Year Results 2008 3ThromboGenics Announces Half Year Results 2008 4ThromboGenics Announces Half Year Results 2008 5
(Date:9/16/2014)... Keystone XL pipeline (KXL) would likely increase oil sands ... surveyed by the non-profit organization Near Zero. The results ... Impact," and includes both supporters and opponents of the ... sands could lead to significantly higher greenhouse gas emissions, ... respond. , "This report examines three main scenarios ...
(Date:9/16/2014)... Southeast Alaska to the white sand beaches of Florida,s ... towns, coastal residents around the U.S. share a common ... lines. That,s a primary finding of a new study ... in the journal Society & Natural Resources . ... place to place to place. Each environment is different ...
(Date:9/16/2014)... 16, 2014  Valencell, Inc., a leader in performance ... of 18 "Showcase Companies" representing North Carolina,s ... CED Tech Venture Conference on September 16-17 th ... in Raleigh, North Carolina . Valencell,s ... discussion during the "Digital Health Spotlight Sector" on how ...
Breaking Biology News(10 mins):Keystone XL would likely raise oil sands production and greenhouse gas emissions 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... have found how two molecules fight in the blood to ... a large protein, which forms a protective shield around cancer ... by a small protein that exists in the blood. ... cancer, infected cells lose growth control and eventually form tumours ...
... prevented the onset of type 1 diabetes in mice ... a receptor on the surface of immune T-cells. According ... in the January issue of the journal Diabetes, have ... , More than 700,000 Americans have type 1 ...
... An immuno-contraceptive vaccine causes an animal's immune system to ... structure in the reproductive process. The antibodies can act ... fertilization or the production of sperm and ova. ... tested nearly 20 years ago, regard it as more ...
Cached Biology News:Scientists discover how body fights to control spread of cancer 2Antibody therapy prevents type 1 diabetes in mice 2Manipulating nature: Scientists query wildlife birth-control method 2
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
... The SelectFX Alexa Fluor 488 Cytochrome ... reagents you need to detect cytochrome c ... anti-cytochrome c primary antibody and an ... Fluor 488 dye exhibits bright green fluorescence ...
Kit for Detection of Mitochondrial Membrane Potential...
MOUSE ANTI NEUROFILAMENTS 140+160 KD...
Biology Products: